Methods and assays for treating filoviridae infections

US9234885B2 · kind B2 · utility

Assignees

• Albert Einstein College of Medicine · US
• President and Fellows of Harvard College · US
• Whitehead Institute For Biomedical Research · US

Inventors

• Kartik Chandran · Brooklyn, US
• Sean Whelan · Birmingham, US
• Thijn R. Brummelkamp · Amsterdam, NL
• Jan E. Carette · Palo Alto, US
• Matthijs Raaben · Amsterdam, NL

Key dates

• Filing date: Jan 24, 2012
• Grant date: Jan 12, 2016
• Expiry date: Mar 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/20243
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus.